A Third, Larger Tesla Model Y Variant Could Debut This Year

We've been waiting a long time for more affordable Teslas, but it seems that the automaker is now looking in the opposite direction. The low-cost Model Y has been delayed, but according to a post on X, Tesla may be on the verge of launching a new variant with more luxurious seating for adults. According to the tweet posted by hacking engineer @greentheonly, a six-seater Model Y has been revealed in firmware, and the code hints that it may be offered globally, not just in China.
The Model Y's 2025.20 update references the six-seater, and with Chinese buyers prioritizing rear legroom, it's no wonder that rumors of such a vehicle have been circulating for a while. Since the code was found in a domestic Model Y, it may not be exclusive to China, so if it comes here, what can we expect? The prevalent theory is that the wheelbase will be extended to accommodate captain's chairs in the middle row, and possibly by as much as 5.9 inches. As Not A Tesla App points out, a 2+2+2 layout would not only be logical, but would also provide reasonable room in the third row. Since the Model X doesn't get armrests with its six-seater configuration, it's unlikely that the cheaper Model Y will, although the option will add thousands to the $46,000 base price.
The 2+2+2 layout would allow Tesla to fit a center console in the second row, which should further enhance the feeling of luxury, but will buyers be willing to shell out extra for a car that looks almost identical from the outside? That remains to be seen, but Tesla may begin to border on oversaturation of the model if there aren't enough differences. A seven-seater Model Y is also on the way with an almost useless third row (at least for the average adult), and one can't help but wonder if these new seating layouts are a lackluster attempt at boosting sales of a car that was once the best-selling on the planet but is now seeing a decline in popularity. Until we see the new Model Y variants later this year (assuming the self-imposed timeline is adhered to), we can't pass fair judgment.
Related: Tesla Isn't Going to Like the All-New Nissan Leaf's Range and Price
Copyright 2025 The Arena Group, Inc. All Rights Reserved.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

29 minutes ago

• Business Upturn

INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]

Yahoo

37 minutes ago

• Yahoo

Don't expect to see Tesla robotaxis everywhere just yet

Tesla's (TSLA) robotaxis are expected to hit the street this weekend in Austin, Texas. Stifel NextGen Transport analyst Stephen Gengaro says that investors shouldn't expect to see a slew of robotaxis hitting the roads across America just yet. Find out why in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Tesla is set to roll out their Robotaxis this weekend, and our next guest today says a successful launch is essential for Tesla to validate the company's long-term pivot toward autonomous mobility. For more, let's welcome in now Stephen Genero, Stephel NextGen transport analyst. Steven, it's good to see you. So, uh, Tesla's robotaxi service rolling out this weekend there in Texas. Steven, what, what do you expect to see and hear and how excited should investors be for this moment? Yeah, hi Josh, and thanks for having me again. So when we think about Tesla in general, right, the RoboTaxi initiative and the full self-driving initiative are critical long term value drivers of the company, and we've talked a lot about that in research notes. When we think about this weekend, I mean, we think this is going to be a slow process, right? This morning you already had some vendors and some, some. A folks, I think there were local local representatives down in Texas wanting to sort of delay the launch till more safety can be checked. But you know this is going to be a slow process. You're probably going to see, you're expected to see 10 or 20 vehicles on the road model wise that are being very closely monitored by Tesla. So this is, you know, a very slow process, but it is obviously, you know, the first step. Something which can be much, much larger over time. And in terms of how, how it expands from here, Stephen, here was Dan Eyes or Wedbush. We know Dan Bull of bulls on Tesla, told his clients that he said, while the Austin launch will start off small with roughly 20 Moo Y vehicles, he says, it's our view. Tesla will launch and scale its Rebo Taxi service to roughly 25 cities in the US over the next year. What do you make of that? Well, it's, I think the first thing that we have to think about, Josh, is, is safety, right? And I think one of the risks to, to the launch is obviously the safety of, of the autonomous driving system and You know, if, if I get in an accident on, on my way to work on Monday, and nobody's going to know or care if a robotaxi, you know, bumps into a fire hydrant, it's going to be in every news feed probably in the world, right? So there has to be a really careful focus on safety. So when we think about, you know, the next steps from here. I do think you're going to see it roll out, you know, over, over the next 2 to 3 quarters in multiple cities in the US, you know, I think it's going to be measured. I think it's going to be a slow process. I mean, when, when we think about the importance of it to Tesla, I don't care that much if it's in 3 cities or 5. or seven cities and you know, by December 30th first, what I care is that if there's a clean launch, it goes smoothly and the safety record is extremely high. And I think, I think Tesla understands that. So while we do build in these significant long term upside potentials for the company and the RoboTaxi is obviously a big part of our evaluation, uh, I think the near term, you know, the focus on safety is more important than how many vehicles are actually out there.

Washington Post

40 minutes ago

• Washington Post

As Musk's 'robotaxi' rollout approaches, Democratic lawmakers in Texas try to throw up a roadblock

NEW YORK — A group of Democratic lawmakers in Texas is asking Elon Musk to delay the planned rollout of driverless 'robotaxis' in the state this weekend to assure that the vehicles are safe. In a letter, seven state legislators asked Tesla to wait until September when a new law takes effect that will require several checks before autonomous vehicles can be deployed without a human in the driver's seat. Tesla is slated to begin testing a dozen of what it calls robotaxis for paying customers on Sunday in a limited area of Austin, Texas.